Natera Announces Signatera Collaboration With Angiex To Develop A Portfolio Of Nuclear-Delivered Antibody-Drug Conjugates
Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and tumor-associated
Natera is teaming up with another company to create new cancer medicines that deliver medicine directly to tumor cells. This shows Natera is growing its cancer-fighting tools, which could help the company in the future, but these medicines are still early in testing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.